Market Research Future published a Half-Cooked Research Report on “Global Vascular
Stents Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake,
Progress, Trends and Forecast to 2023.
Global Vascular Stents Market - Overview
Vascular stents are tiny tube like medical devices which are places into blood vessels or
arteries to open the blockage in the vessels. Vascular stent is the valuable tool for the
treatment of the different coronary diseases. Vascular stents are used to widen the narrow
vessels so as to minimize the chances of heart attack and chest pain. This stents are
prepared from variety of material. According to the WHO, approximately 18 million people
died from cardiovascular diseases in 2014. Increasing number of people suffering from
cardiovascular diseases is responsible for the driving the market. Additionally, globally 39%
of adults aged 18 years and over were overweight whereas 13% were obese. Technological
advances and increasing obese population is also contributed in the growth of the market.
Other advantages like low risk of infection and short recovery time will also drive the
market. However availability of alternative therapy and high cost of ventricular stents may
restrain the growth of the market.
Get Premium Sample Copy @
Global Vascular Stents Market - Competitive Analysis
Boston Scientific Corporation (US), Abbott Laboratories (US), Medtronic, Plc (UK), Cook
Medical (US), Biotronik se & co. kg (Germany), B. Braun Melsungen AG (Germany), Cordis
(US), Lombard Medical Technologies (UK), Translumina GmbH (Germany), MicroPort
Scientific Corporation (China), Terumo Corporation (Japan), Vascular Concepts (India), W.L.
Gore & Associates (US), Meril Life Sciences Pvt. Ltd. (India) are some of the prominent
players at the forefront of competition in the Global Vascular Stents Market and are profiled
in MRFR Analysis.
Many companies are focusing on research and development activity to improve the vascular
stent products. Major companies are focusing on the development of biodegradable stents
to overcome the disadvantages of other available stents. Some major has adopted
strategies of acquisitions and strategic alliances for the growth of the market.
Abbott Laboratories is one of the leading healthcare company headquartered in US. In June
2016, FDA has approved the Absorb bioresorbable Stent for heart. This stents is completely
dissolve in the body and used in the treatment of heart complications. Company’s Esprit
bioresorbable vascular scaffold is under clinical trials.
December, 2016 - Lombard Medical and MicroPort Scientific Corporation announced
strategic partnership and investment agreement. This partnership allowed Lombard Medical
to accelerate commercialization in global market with its two key products i.e Aorfix and
Altura AAA. Aorfix, the only stent graft to hold global approvals to treat abdominal aortic
aneurysms (AAA) with aortic neck angles up to 900, and Altura, a highly innovative stent
graft that offers a simple and predictable treatment option for standard abdominal aortic
Boston Scientific Corporation is a global manufacturer and developer of medical devices
headquartered in US. PROMUS Element Plus Stent, REBEL Stent System, SYNERGY Stent
are some of the major products of the company. In 2014, company has launched Promus
PREMIER Everolimus-eluting Platinum Chromium Coronary Stent System in Asia Pacific
region. In 2015, worldwide sales of the company’s drug-eluting coronary stents were
$1.074 billion as compared to $1.151 billion during 2014.
Medtronic is a medical device manufacturer headquartered in UK. It is the world's largest
standalone medical technology development company. In 2015 company has develop Stent
Graft System System for Endovascular Repair of Thoracoabdominal Aortic Aneurysms.
Earlier company’s Resolute Drug-Eluting Stent has shown a very good performance in
Diabetic Patients with Heart Disease. Medtronic market was increased by 7% in 2016
compared to 2015.